{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:53:10Z","timestamp":1771653190510,"version":"3.50.1"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.18632\/oncotarget.11100","type":"journal-article","created":{"date-parts":[[2016,8,7]],"date-time":"2016-08-07T00:38:23Z","timestamp":1470530303000},"page":"72311-72321","source":"Crossref","is-referenced-by-count":27,"title":["Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients"],"prefix":"10.18632","volume":"7","author":[{"given":"Monica","family":"Bocchia","sequence":"first","affiliation":[{"name":"Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Aprile","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[{"name":"Functional Unit of Hematology, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Santilli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, University of Chieti, Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Scappini","sequence":"additional","affiliation":[{"name":"Functional Unit of Hematology, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fontanelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika Malgorzata","family":"Trawinska","sequence":"additional","affiliation":[{"name":"Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Defina","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Functional Unit of Hematology, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Puccetti","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Falge","year":"2015","journal-title":"Leukemia"},{"key":"2","first-page":"1","article-title":"Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"16","author":"Alimena","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"11","author":"Akard","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System","volume":"90","author":"Wallis","year":"2015","journal-title":"Am J Hematol"},{"key":"5","first-page":"1","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"20","author":"Hillis","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"6","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Deininger","year":"2015","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Valent","year":"2011","journal-title":"Am J Hematol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Valent","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"9","first-page":"1489","article-title":"Arterial occlusive disease (PAOD) in patients (Pts) receiving dasatinib: experience across multiple clinical trials","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood ASH annual meeting abstract"},{"key":"10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Saglio","year":"2013","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Haverkamp","year":"2013","journal-title":"Leukemia"},{"key":"12","first-page":"1","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment","volume":"5","author":"Jamroziak","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"le Coutre","year":"2015","journal-title":"Blood"},{"key":"14","first-page":"124","article-title":"Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML","author":"Rix","year":"2014","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Cortes","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"16","first-page":"124","article-title":"Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib","author":"Feldman","year":"2014","journal-title":"Blood"},{"key":"17","first-page":"124","article-title":"Incidence of Vascular Thrombotic Events in 183 Consecutive Patients Treated with Nilotinib: A Single Centre Experience","author":"Milojkovic","year":"2014","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Alimena","year":"2015","journal-title":"Ann Hematol"},{"key":"19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11523-016-0417-x","article-title":"Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy","volume":"11","author":"Montastruc","year":"2016","journal-title":"Target Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Messas","year":"2015","journal-title":"Eur J Haematol"},{"key":"21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5482\/HAMO-13-09-0050","article-title":"Inflammatory mechanisms in atherosclerosis","volume":"34","author":"Zirlik","year":"2014","journal-title":"Hamostaseologie"},{"key":"23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10557-011-6325-5","article-title":"LOX-1: a new target for therapy for cardiovascular diseases","volume":"25","author":"Sawamura","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/03014460903393857","article-title":"Population differences in allele frequencies at the OLR1 locus may suggest geographic disparities in cardiovascular risk events","volume":"37","author":"Novelli","year":"2010","journal-title":"Ann Hum Biol"},{"key":"25","first-page":"30012","article-title":"Roles of LOX-1 in microvascular dysfunction","volume":"18","author":"Balzan","year":"2016","journal-title":"Microvasc Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Assmann","year":"2012","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1373\/clinchem.2008.112243","article-title":"Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer","volume":"54","author":"Kyrle","year":"2008","journal-title":"Clin Chem"},{"key":"28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.clinbiochem.2009.12.021","article-title":"Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions","volume":"43","author":"Ferroni","year":"2010","journal-title":"Clin Biochem"},{"key":"29","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2013.112","article-title":"Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10557-011-6333-5","article-title":"LOX-1\/LOXIN: the yin\/yang of atheroscleorosis","volume":"25","author":"Novelli","year":"2011","journal-title":"Cardiovasc Drug Ther"},{"key":"31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/ageing\/afs074","article-title":"Circulating oxidised LDL lipids, when proportioned to HDL-c, emerged as a risk factor of all-cause mortality in a population-based survival study","volume":"42","author":"Vasankari","year":"2013","journal-title":"Age Ageing"},{"key":"32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2013.10.026","article-title":"Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population","volume":"232","author":"Fit\u00f3","year":"2014","journal-title":"Atherosclerosis"},{"key":"33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11739-007-0076-0","article-title":"CD40\/CD40L system and vascular disease","volume":"2","author":"Dav\u00ec","year":"2007","journal-title":"Intern Emerg Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/cvr\/cvn120","article-title":"Cytokines and atherosclerosis: a comprehensive review of studies in mice","volume":"79","author":"Kooistra","year":"2008","journal-title":"Cardiovasc Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/eurheartj\/ehr262","article-title":"Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"33","author":"Sattar","year":"2012","journal-title":"Eur Heart J"},{"key":"36","doi-asserted-by":"crossref","first-page":"R1250","DOI":"10.1152\/ajpregu.00227.2003","article-title":"C-reactive protein: A surrogate risk marker or mediator of atherothrombosis?","volume":"285","author":"Ridker","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/ars.2013.5790","article-title":"Clinical Application of NOX Activity and Other Oxidative Biomarkers in Cardiovascular Disease: A Critical Review","volume":"23","author":"Pignatelli","year":"2015","journal-title":"Antioxid Redox Signal"},{"issue":"Suppl 1","key":"38","first-page":"S1","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Hobbs","year":"2011","journal-title":"Atherosclerosis"},{"key":"39","first-page":"514","article-title":"ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"23","author":"Watson","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/1479164113489042","article-title":"Effect of IL-10 on LOX-1 expression, signaling and functional activity: an atheroprotective response","volume":"10","author":"Chandra","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"41","first-page":"1","article-title":"LOX-1 and its implications on cardiovascular diseases a possible new perspective target on atherosclerosis","volume":"4","author":"Dei Cas","year":"2013","journal-title":"J Clin Exp Cardiol"},{"key":"42","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Criqui","year":"2013","journal-title":"Lancet"},{"key":"43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/HJR.0b013e3283361ce6","article-title":"Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study","volume":"17","author":"Algra","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:34:03Z","timestamp":1589290443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":43,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["11100","27527867"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11100","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]}}}